Issues and legislative proposals on biosimilars and generics medicines, including but not limited to generics and biosimilar sustainability, pharmaceutical supply chain security, drug shortages, interchangeability, patent litigation, and PBM reform
Source-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 17, 2026
- Income
- $80,000.00
- Expenses
- Not reported
- Registrant
- S-3 GROUP
- Client
- SANDOZ INC.
- Filing UUID
- bf36e34f-caa9-41d8-83a1-79f28339db0d
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.